Fresenius Medical Care AG (BIT:1FME)
Italy · Delayed Price · Currency is EUR | Market Cap | 9.62B -22.1% |
| Revenue (ttm) | 19.36B -0.7% |
| Net Income | 945.37M +52.9% |
| EPS | 3.30 +56.5% |
| Shares Out | n/a |
| PE Ratio | 10.18 |
| Forward PE | 27.89 |
| Dividend | 1.49 (3.86%) |
| Ex-Dividend Date | May 22, 2026 |
| Volume | n/a |
| Average Volume | 369 |
| Open | 36.22 |
| Previous Close | 35.90 |
| Day's Range | 36.22 - 36.90 |
| 52-Week Range | 34.68 - 53.42 |
| Beta | n/a |
| RSI | 36.38 |
| Earnings Date | May 5, 2026 |
About Fresenius Medical Care AG
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient’s residence; and dialysis services under contract to hospitals in the United States for the hospital... [Read more]
Financial Performance
In 2025, Fresenius Medical Care AG's revenue was 19.63 billion, an increase of 1.51% compared to the previous year's 19.34 billion. Earnings were 978.37 million, an increase of 81.88%.
Financial StatementsNews
Q1 2026 Fresenius Medical Care AG Earnings Call Transcript
Q1 2026 Fresenius Medical Care AG Earnings Call Transcript
Relative Strength Alert For Fresenius Medical Care
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a tec...
EQS-CMS: Fresenius Medical Care AG : Release according to Article 50 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Post-admission Duties announcement: Fresenius Medical Care AG / Third country release according to Article 50 Para. 1, No. 2 of the WpHG [the German Securities Trading Act] Fresenius Medical Care ...
Fresenius Medical Care AG Earnings Call Transcript: Q1 2026
Solid Q1 performance with 4% organic revenue and 10% operating income growth, driven by margin expansion, FME25+ savings, and accelerated 5008X rollout. Outlook for 2026 remains stable, with inflation and regulatory risks closely monitored.
Fresenius Medical Care delivers strong operating income growth in Q1 2026 while advancing the U.S. rollout of 5008X CAREsystems at speed
Organic revenue growth1 of 4% with growth in all operating segments Operating income2 grew 10%, resulting in further margin expansion to 10.1% FME25+ transformation program related one-time costs main...
Fresenius Medical Care delivers strong operating income growth in Q1 2026 while advancing the U.S. rollout of 5008X CAREsystems at speed
Organic revenue growth 1 of 4% with growth in all operating segments Operating income 2 grew 10%, resulting in further margin expansion to 10.1% FME25+ transformation program related one-time costs ma...
Palantir stark, ON Semi solide, Nebius im Höhenflug
In der heutigen Sendung geht es um diese Werte: Secunet Security Networks, CTS Eventim, Deutsche Post, Fresenius Medical Care, Norwegian Cruise Line, Berkshire Hathaway, Amazon, Duolingo, On Semicondu...
Fresenius Medical Care Posts Lower Net Profit on One-Off Costs
The dialysis specialist started restructuring its U.S. network by exiting 64 of up to 100 clinics.
Fresenius Medical Care's revenue falls in Q1 as weak dollar takes toll
Fresenius Medical Care said on Tuesday its revenue fell 6% in the first quarter of 2026, weighed down by significant currency effects, mainly from the weak U.S. dollar, and recent divestitures.
Humacyte Expands Commercial and Business Development Opportunities Through Realignment of Ex-U.S. Rights to Symvess
- Ex-U.S. rights realigned under amendment to distribution agreement with Fresenius Medical Care - - Positions Humacyte to advance discussions with corporate partners regarding international and indic...
Quest Diagnostics Q1 2026 Earnings Call: Complete Transcript
Quest Diagnostics (NYSE: DGX) released first-quarter financial results and hosted an earnings call on Tuesday. Read the complete transcript below. Benzinga APIs provide real-time access to earnings c...
EQS-CMS: Fresenius Medical Care AG : Release of a capital market information
EQS Post-admission Duties announcement: Fresenius Medical Care AG / Disclosure pursuant to Art. 5 para. 1 lit. b) of Regulation (EU) No. 596/2014 Fresenius Medical Care AG : Release of a capital marke...
Fresenius Medical Care AG Earnings Call Transcript: Q4 2025
Delivered strong 2025 results with record profitability, robust cash flow, and margin expansion, supported by strategic initiatives and cost savings. 2026 is expected to be a transition year with flat earnings amid regulatory headwinds and major investments, but long-term growth and margin targets remain intact.
Fresenius Medical Care delivers 27% earnings growth in 2025 and reaches upper end of its financial outlook; margin within 2025 mid-term target band
Strong organic revenue growth1 in 2025 of 8% driven by all operating segments Driven by an exceptional Q4, full year operating income2 growth of 27% reached top end of financial outlook, resulting in ...
Fresenius Medical Care Shares Drop After Outlook, U.S. Performance Underwhelms
Shares in the dialysis specialist were down 7.1% in European midday trade, with the decline erasing gains since the start of 2026.
Fresenius Medical Care AG Earnings Call Transcript: Q4 2025
Strong 2025 results with 8% organic revenue growth, 31% higher operating income, and 44% EPS growth. 2026 is a transition year with flat revenue expected, significant investment in U.S. HDF rollout, and continued focus on operational excellence and margin improvement.
Fresenius Medical Care's operating profit surges in Q4
Fresenius Medical Care reported a sharp rise in fourth‑quarter operating income on Tuesday, helped by accelerating cost savings and favourable reimbursement effects.
Fresenius Medical Care AG Transcript: 44th Annual J.P. Morgan Healthcare Conference
A clear growth strategy is underway, highlighted by the U.S. rollout of high-volume HDF therapy and a focus on operational excellence. Financial performance is strong, with improved margins, accelerated share buybacks, and robust cash flow, while 2026 is set as a transition year for major infrastructure upgrades.
Fresenius Medical Care accelerates the second tranche of its EUR 1 billion share buyback program with around EUR 415 million repurchase planned
The second tranche of the share buyback is expected to be executed by May 8, 2026 The share buyback program with a total volume of EUR 1 billion is expected to be completed in less than a year, signif...
Fresenius Medical Care appoints Charles Hugh-Jones as Global Chief Medical Officer and member of the Management Board
Effective January 1, 2026, Charles Hugh-Jones will join the Management Board as Global Chief Medical Officer As part of a planned transition Franklin W. Maddux will retire by year end BAD HOMBURG, Ger...
Fresenius Medical Care AG Earnings Call Transcript: Q3 2025
Q3 delivered 10% organic revenue growth and 28% operating income growth, with margin expansion to 11.7%. All segments contributed, FME25+ savings accelerated, and the share buyback progressed. Full-year guidance is reiterated, with strong Q4 and 2026 outlook dependent on regulatory and market factors.
Fresenius Medical Care further accelerates organic revenue development and achieves an inflection in earnings growth, delivering 28% operating income growth in the third quarter of 2025
Strong organic revenue growth1 of 10% driven by all operating segments Positive U.S. same market treatment growth of 0.1 % in line with expectations Accelerated operating income2 growth of 28% at cons...
Fresenius Medical Care beats quarterly profit estimates helped by cost cuts
Fresenius Medical Care reported a third-quarter operating income that exceeded analysts' expectations on Tuesday, in a sign that the dialysis specialist's cost-cutting measures were beginning to take ...
Fresenius Medical Care highlights real-world advances in hemodiafiltration and AI at ASN Kidney Week 2025
Fresenius Medical Care researchers will present multiple abstracts that demonstrate proven, real-world benefits of hemodiafiltration (HDF), with one accepted as an oral presentation. Oral presentation...
Fresenius Medical Care appoints Joseph Turk as new Management Board Member for Care Enablement
Effective January 1, 2026, Joseph Turk will join the Management Board as Chief Executive Officer of the global operating segment Care Enablement As part of a planned transition Dr. Katarzyna Mazur-Hof...